sellWeak cluster of 410b5-1 plan
Dana Pizzuti sold $86k of CRNX
Chief Med and Dev Officer at Crinetics Pharmaceuticals, Inc.. 2,515 shares at an average of $34.20, traded Mar 19, 2025, filed Mar 21, 2025.
Warning score
19Value
$86k
2,515 shares
Holdings after
72,233
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +9Trade size$86k at market
- 0Share of holdings soldSold 3.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-043407, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 19, 2025 | SOpen-market sale Common Stock10b5-1 | -2,388 | $34.17 | $82k | 72,360 | Mar 21, 2025 |
| Mar 19, 2025 | SOpen-market sale Common Stock10b5-1 | -127 | $34.83 | $4,423 | 72,233 | Mar 21, 2025 |
Related signals
Other insiders at Crinetics Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $3.1M 97,483 shares | -49% | |
| 22Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $197k 5,770 shares | -5% | |
| 39Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $593k 17,338 shares | -5% | |
| 28Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $245k 7,162 shares | -8% | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $195k 5,000 shares | -14% | |
| 12Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $781k 15,000 shares | -34% | |
| 32Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $576k 10,000 shares | -9% | |
| 13Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $28k 501 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.